Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) Return on Equity (2018 - 2025)

Dianthus Therapeutics has reported Return on Equity over the past 7 years, most recently at 0.3% for Q3 2025.

  • Quarterly results put Return on Equity at 0.3% for Q3 2025, down 9.0% from a year ago — trailing twelve months through Sep 2025 was 0.3% (down 9.0% YoY), and the annual figure for FY2024 was 0.32%, up 37.0%.
  • Return on Equity for Q3 2025 was 0.3% at Dianthus Therapeutics, up from 0.37% in the prior quarter.
  • Over the last five years, Return on Equity for DNTH hit a ceiling of 2.43% in Q2 2022 and a floor of 0.91% in Q1 2022.
  • Median Return on Equity over the past 4 years was 0.19% (2024), compared with a mean of 0.1%.
  • Peak annual rise in Return on Equity hit 101bps in 2023, while the deepest fall reached -253bps in 2023.
  • Dianthus Therapeutics' Return on Equity stood at 0.52% in 2022, then tumbled by -148bps to 0.25% in 2023, then increased by 2bps to 0.24% in 2024, then decreased by -23bps to 0.3% in 2025.
  • The last three reported values for Return on Equity were 0.3% (Q3 2025), 0.37% (Q2 2025), and 0.29% (Q1 2025) per Business Quant data.